Search

Displaying results 1001 - 1010 of 4598 in total
  1. Drug

    GLPG-1205

    go.drugbank.com/drugs/DB15346
    Investigational

    GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).

  2. Drug

    Sennosides

    go.drugbank.com/drugs/DB11365
    ApprovedInvestigational

    The medication is taken by mouth or via the rectum[FDA Label]. It typically begins working in minutes when given by rectum and within twelve hours when given by mouth[FDA Label].

    Mixtures: Konsyl Overnight Relief Senna Prompt
  3. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … to be approved by the FDA.

  4. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.

  5. Drug

    Opium

    go.drugbank.com/drugs/DB11130
    ApprovedIllicit

    [A32175] Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. … During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive.[A32171] Opium is extracted from _Papaver somniferum_, which is more known as poppies.

  6. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190492] Later that year in December, the drug was also approved by the European Medicine Agency.[A190492] In June 2012, fidaxomicin was also granted approval by Health Canada. … [A7445] It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription.

  7. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.

  8. Drug

    Tazobactam

    go.drugbank.com/drugs/DB01606
    ApprovedInvestigational

    Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.

  9. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.

  10. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    The transmembrane NKG2D and intracellular 2B4 domains are required for optimal NK signalling and subsequent cell-mediated cytotoxicity. … These cells are prepared as universal off-the-shelf CAR-NK cells from cord blood with NKG2D-ACE2 proteins engineered as part of the CARs; the cell secretes IL-15 and GM-CSF.

    Synonyms: ACE2 CAR-NK Cell, NKG2D CAR-NK Cell